Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Netarsudil dosing in Fuchs corneal dystrophy
NCT04498169Phase 2Completed
- Sponsor
- Aerie Pharmaceuticals
- Start
- Sep 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of netarsudil in Fuchs endothelial dystrophy (FED), sponsored by Aerie Pharmaceuticals. Started Sep 2020; status: completed.
02
Drugs
netarsudil
03
Conditions
Fuchs endothelial dystrophy (FED)
Beyond the preview
Go deeper on NCT04498169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04498169.